Mediar Therapeutics Enters into Global Licensing Agreement with Lilly to Advance First-in-Class WISP1 Antibody for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
Mediar to advance MTX-463 through an IPF Phase 2 trial, with expected initiation in 1H 2025